Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Jan

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Chemoradiation Plus Atezolizumab in Limited-Stage Small Cell Lung Cancer

Locoregionally Advanced Nasopharyngeal Carcinoma: Comparison of Regimens Following Induction Chemotherapy

Bacterial Decolonization to Manage Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma

New Liquid Biopsy Test for Early Detection of Head and Neck Cancers